ImmuPharma (LON:IMM) Trading Up 12.8% – Should You Buy?

ImmuPharma plc (LON:IMMGet Free Report) shares shot up 12.8% during trading on Monday . The stock traded as high as GBX 4.95 ($0.06) and last traded at GBX 4.44 ($0.06). 11,150,036 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 19,209,219 shares. The stock had previously closed at GBX 3.94 ($0.05).

ImmuPharma Stock Down 20.0 %

The stock has a market cap of £19.66 million, a PE ratio of -472.00 and a beta of 1.53. The company has a fifty day moving average price of GBX 1.92 and a 200 day moving average price of GBX 1.78.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.